135 related articles for article (PubMed ID: 7743513)
41. The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells.
Soltermann A; Ernst A; Leroy D; Stahel RA; Gasser SM
Exp Cell Res; 1999 Jun; 249(2):308-19. PubMed ID: 10366430
[TBL] [Abstract][Full Text] [Related]
42. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
43. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
Takigawa N; Ohnoshi T; Ueoka H; Yonei T; Kiura K; Tabata M; Kodani T; Kamei H; Segawa Y; Shibayama T
Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
[TBL] [Abstract][Full Text] [Related]
44. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
45. Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase II alpha gene promoter.
Loflin PT; Hochhauser D; Hickson ID; Morales F; Zwelling LA
Biochem Biophys Res Commun; 1994 Apr; 200(1):489-96. PubMed ID: 8166723
[TBL] [Abstract][Full Text] [Related]
46. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
47. Differential expression of nuclear envelope lamins A and C in human lung cancer cell lines.
Kaufmann SH; Mabry M; Jasti R; Shaper JH
Cancer Res; 1991 Jan; 51(2):581-6. PubMed ID: 1985776
[TBL] [Abstract][Full Text] [Related]
48. The novel human HUEL (C4orf1) gene maps to chromosome 4p12-p13 and encodes a nuclear protein containing the nuclear receptor interaction motif.
Sim DL; Chow VT
Genomics; 1999 Jul; 59(2):224-33. PubMed ID: 10409434
[TBL] [Abstract][Full Text] [Related]
49. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K
Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635
[TBL] [Abstract][Full Text] [Related]
50. Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples.
Dingemans AM; Van Ark-Otte J; Smit EF; Postmus PE; Giaccone G
Anticancer Res; 2000; 20(5B):3549-54. PubMed ID: 11131661
[TBL] [Abstract][Full Text] [Related]
51. Expression of topoisomerases II alpha and beta in Chinese hamster lung cells resistant to topoisomerase II inhibitors.
Khélifa T; Casabianca-Pignède MR; René B; Jacquemin-Sablon A
Mol Pharmacol; 1994 Aug; 46(2):323-8. PubMed ID: 8078494
[TBL] [Abstract][Full Text] [Related]
52. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
53. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.
Evans CD; Mirski SE; Danks MK; Cole SP
Cancer Chemother Pharmacol; 1994; 34(3):242-8. PubMed ID: 8004758
[TBL] [Abstract][Full Text] [Related]
54. Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I.
Hasegawa T; Isobe K; Nakashima I; Shimokata K
Biochem Biophys Res Commun; 1993 Aug; 195(1):409-14. PubMed ID: 8395833
[TBL] [Abstract][Full Text] [Related]
55. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
56. Impairment of Moloney murine leukemia virus integration in a cell line underexpressing DNA topoisomerase II.
Bouillé P; Subra F; Goulaouic H; Carteau S; Auclair C
Cancer Res; 1995 Jul; 55(14):3211-7. PubMed ID: 7606743
[TBL] [Abstract][Full Text] [Related]
57. Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo.
Prosperi E; Sala E; Negri C; Oliani C; Supino R; Astraldi Ricotti GB; Bottiroli G
Anticancer Res; 1992; 12(6B):2093-9. PubMed ID: 1338275
[TBL] [Abstract][Full Text] [Related]
58. Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha.
de Lucio B; Manuel V; Barrera-Rodríguez R
Cancer Sci; 2005 Nov; 96(11):774-83. PubMed ID: 16271071
[TBL] [Abstract][Full Text] [Related]
59. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
60. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
